Publications :: OPKO Health, Inc. (OPK)

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Read the news release

Visit BioReference Health

PubMed

Apr 28, 2024

Extended-Release Calcifediol: A Data Journey from Phase 3 Studies to Real-World Evidence Highlights the Importance of Early Treatment of Secondary Hyperparathyroidism

JCEM

Nov 7, 2023

Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis

Nature Communications

Jun 15, 2023

Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections

Journals

Mar 28, 2023

Factors in nephrologists’ decision to treat pre-dialysis CKD patients with vitamin D insufficiency and SHPT: A discrete choice experiment

PubMed

Feb 28, 2023

Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease

PubMed

Nov 28, 2022

Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients

PubMed

Nov 28, 2022

REsCue trial: Randomized controlled clinical trial with extended-release calcifediol in symptomatic COVID-19 outpatients

PubMed

May 28, 2022

Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary Hyperparathyroidism

Science Translational Medicine

May 15, 2022

A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice

Nature

Feb 15, 2022

A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells